title: Tyrosine kinase, aurora kinase and leucine aminopeptidase as attractive drug targets in anticancer therapy - characterisation of their inhibitors.
abstract: Cancers are the leading cause of deaths all over the world. Available anticancer agents used in clinics exhibit low therapeutic index and usually high toxicity. Wide spreading drug resistance of cancer cells induce a demanding need to search for new drug targets. Currently, many on-going studies on novel compounds with potent anticancer activity, high selectivity as well as new modes of action are conducted. In this work, we describe in details three enzyme groups, which are at present of extensive interest to medical researchers and pharmaceutical companies. These include receptor tyrosine kinases (e.g. EGFR enzymes) and non-receptor tyrosine kinases (Src enzymes), type A, B and C Aurora kinases and aminopeptidases, especially leucine aminopeptidase. We discuss classification of these enzymes, biochemistry as well as their role in the cell cycle under normal conditions and during cancerogenesis. Further on, the work describes enzyme inhibitors that are under in vitro, preclinical, clinical studies as well as drugs available on the market. Both, chemical structures of discovered inhibitors and the role of chemical moieties in novel drug design are discussed. Described enzymes play essential role in cell cycle, especially in mitosis (Aurora kinases), cell differentiation, growth and apoptosis (tyrosine kinases) as well as G1/S transition (leucine aminopeptidase). In cancer cells, they are overexpressed and only their inhibition may stop tumor progression. This review presents the clinical outcomes of selected inhibitors and argues the safety of drug usage in human volunteers. Clinical studies of EGFR and Src kinase inhibitors in different tumors clearly show the need for molecular selection of patients (to those with mutations in genes coding EGFR and Src) to achieve positive clinical response. Current data indicates the great necessity for new anticancer treatment and actions to limit off-target activity.
authors.affiliation: National Institute of Public Health – National Institute of Hygiene, Laboratory of Biologically Active Compounds, 24 Chocimska Str., 00-791 Warsaw, Poland
authors.forename: Joanna
authors.initials: J
authors.lastname: Ziemska
authors.affiliation: National Institute of Public Health – National Institute of Hygiene, Laboratory of Biologically Active Compounds, 24 Chocimska Str., 00-791 Warsaw, Poland
authors.forename: Jolanta
authors.initials: J
authors.lastname: Solecka
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D064127:Aurora Kinases; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007931:Leucyl Aminopeptidase; D009369:Neoplasms / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011505:Protein-Tyrosine Kinases; D064127:Aurora Kinases; D007931:Leucyl Aminopeptidase